Exscientia Ltd., the UK-based company that automates drug design with its AI-based platform, has added cancer specialist Roche to its growing list of pharma collaborators while also raising $26m in a Series B financing that will be used to aggressively expand its own pipeline in coming years.
Founded in 2012, Exscientia has been steadily expanding on the back of growing acceptance and use of artificial intelligence in drug innovation
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?